Back to Search
SHAUN LAURIE, M.D.
M.D.
Internal Medicine Physician
NPI: 1952344285IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
ME70462(FL)
CMS Specialties
PrimaryINTERNAL MEDICINE
Education
UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE
Class of 1993
Research & Publications (20)
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.
PMID 19309723·Head Neck·2009
3-trial
Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status.
PMID 19289623·J Clin Oncol·2009
3-trial
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.
PMID 19091548·Eur J Cancer·2009
3-trial
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.
PMID 19047292·J Clin Oncol·2009
8-other
NICE on lipid modification: NICE's simplified approach to lipids will not work.
PMID 18556285·BMJ·2008
8-other
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.
PMID 18398152·J Clin Oncol·2008
3-trial
Outcomes of second-line chemotherapy in patients with relapsed extensive small cell lung cancer.
PMID 18303438·J Thorac Oncol·2008
8-other
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
PMID 17761983·J Clin Oncol·2007
3-trial
Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185.
PMID 17710208·Curr Oncol·2007
8-other
The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: a combined analysis of studies of the National Cancer Institute of Canada Clinical Trials Group.
PMID 17586749·Ann Oncol·2007
4-observational
Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients.
PMID 17409893·J Thorac Oncol·2006
3-trial
Association between anemia arising during therapy and outcomes of chemoradiation for limited small-cell lung cancer.
PMID 17409844·J Thorac Oncol·2006
8-other
American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer.
PMID 16832122·J Clin Oncol·2006
6-review
Systemic therapy in the palliative management of advanced salivary gland cancers.
PMID 16763282·J Clin Oncol·2006
6-review
A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization.
PMID 16638865·Clin Cancer Res·2006
3-trial
Phase I study of green tea extract in patients with advanced lung cancer.
PMID 15309507·Cancer Chemother Pharmacol·2005
3-trial
Safety of rush immunotherapy to multiple aeroallergens in an adult population.
PMID 15104192·Ann Allergy Asthma Immunol·2004
4-observational
Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer.
PMID 14739044·Lung Cancer·2004
6-review
Highly conserved protein kinases involved in the regulation of carbon and amino acid metabolism.
PMID 14645392·J Exp Bot·2004
6-review
Metabolic signalling and carbon partitioning: role of Snf1-related (SnRK1) protein kinase.
PMID 12508057·J Exp Bot·2003
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1628 N PLAZA DR
TALLAHASSEE, FL 32308 - Phone
- (850) 309-1331
Quick Facts
- NPI
- 1952344285
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 33
- Publications
- 20
Are you this provider?
Claim Your Profile